Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Rhabdomyosarcoma 1Myelodysplastic Syndromes 1Meningeal Carcinomatosis 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 24Vincristine 19Doxorubicin 17Radiotherapy 14Prednisone 13Methotrexate 13Cytarabine 13Rituximab 11Dexamethasone 11pegaspargase 10Filgrastim 10Etoposide 10Mercaptopurine 9Calcium Dobesilate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8azathiopurine 8auricularum 8Thioguanine 8Leucovorin 8Radiation 7Daunorubicin 7prednylidene 6deltacortene 6Asparaginase 6blinatumomab 5Prednisolone 5Peripheral Blood Stem Cell Transplantation 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Burkitt Lymphoma × Spinal Puncture × Clear all
NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡